King's College London

Research portal

Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA

Research output: Contribution to journalArticle

Standard

Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. / Pavlidis, Polychronis; Shums, Zakera; Koutsoumpas, Andreas; Milo, Jay; Papp, Maria; Umemura, Takeji; Lakatos, Peter L.; Smyk, Daniel S.; Bogdanos, Dimitrios P.; Forbes, Alastair; Norman, Gary L.

In: Clinica Chimica Acta, Vol. 441, 04.02.2015, p. 176-181.

Research output: Contribution to journalArticle

Harvard

Pavlidis, P, Shums, Z, Koutsoumpas, A, Milo, J, Papp, M, Umemura, T, Lakatos, PL, Smyk, DS, Bogdanos, DP, Forbes, A & Norman, GL 2015, 'Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA', Clinica Chimica Acta, vol. 441, pp. 176-181. https://doi.org/10.1016/j.cca.2014.12.010

APA

Pavlidis, P., Shums, Z., Koutsoumpas, A., Milo, J., Papp, M., Umemura, T., Lakatos, P. L., Smyk, D. S., Bogdanos, D. P., Forbes, A., & Norman, G. L. (2015). Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. Clinica Chimica Acta, 441, 176-181. https://doi.org/10.1016/j.cca.2014.12.010

Vancouver

Pavlidis P, Shums Z, Koutsoumpas A, Milo J, Papp M, Umemura T et al. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. Clinica Chimica Acta. 2015 Feb 4;441:176-181. https://doi.org/10.1016/j.cca.2014.12.010

Author

Pavlidis, Polychronis ; Shums, Zakera ; Koutsoumpas, Andreas ; Milo, Jay ; Papp, Maria ; Umemura, Takeji ; Lakatos, Peter L. ; Smyk, Daniel S. ; Bogdanos, Dimitrios P. ; Forbes, Alastair ; Norman, Gary L. / Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. In: Clinica Chimica Acta. 2015 ; Vol. 441. pp. 176-181.

Bibtex Download

@article{caffdc57c7f94e2a9e5fc25bf3e19498,
title = "Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA",
abstract = "Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.",
keywords = "Autoantibody, Bowel disease, Marker, Sensitivity, Specificity",
author = "Polychronis Pavlidis and Zakera Shums and Andreas Koutsoumpas and Jay Milo and Maria Papp and Takeji Umemura and Lakatos, {Peter L.} and Smyk, {Daniel S.} and Bogdanos, {Dimitrios P.} and Alastair Forbes and Norman, {Gary L.}",
year = "2015",
month = feb,
day = "4",
doi = "10.1016/j.cca.2014.12.010",
language = "English",
volume = "441",
pages = "176--181",
journal = "Clinica Chimica Acta",
issn = "0009-8981",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA

AU - Pavlidis, Polychronis

AU - Shums, Zakera

AU - Koutsoumpas, Andreas

AU - Milo, Jay

AU - Papp, Maria

AU - Umemura, Takeji

AU - Lakatos, Peter L.

AU - Smyk, Daniel S.

AU - Bogdanos, Dimitrios P.

AU - Forbes, Alastair

AU - Norman, Gary L.

PY - 2015/2/4

Y1 - 2015/2/4

N2 - Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.

AB - Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.

KW - Autoantibody

KW - Bowel disease

KW - Marker

KW - Sensitivity

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=84921515346&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.12.010

DO - 10.1016/j.cca.2014.12.010

M3 - Article

C2 - 25512163

AN - SCOPUS:84921515346

VL - 441

SP - 176

EP - 181

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454